Apellis Pharmaceuticals has announced that it has finalized the trial design for its planned Phase 3 program evaluating APL-2 for the treatment of patients with geographic atrophy (GA), aka dry macular degeneration. The Phase 3 program, planned to begin in the second half of 2018, will consist of two identical studies to assess the efficacy [Read More]
News
FDA Approves First Gene Therapy for Inherited Retinal Dystrophy
The U.S. Food and Drug Administration (FDA) has approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy developed by Spark Therapeutics, to treat an inherited form of vision loss that can result in blindness. The most prevalent inherited retinal dystrophies are retinitis pigmentosa (RP), Leber congenital amaurosis (LCA) and Stargardt disease (SD), all of which have [Read More]
Help Your Ophthalmologist Help You
Please share this article with your ophthalmologist Vision rehabilitation is the standard of care for patients who are losing their vision, and ophthalmologists are key to improving access to care for these patients. Recognizing this, Lighthouse Guild is offering ophthalmologists free access to an eLearning program titled, “Introduction to Vision Rehabilitation.” Dr. Alan R. Morse, [Read More]
Iluvian Continues to Show Good Results in DME Trials
We reported here in 2015 that Iluvian, a unique drug implant devised by Alimera Sciences, had entered trials for treatment of diabetic macular edema (DME). The drug is a corticosteroid that has demonstrated effectiveness in the treatment of DME without the need for monthly injections. Jay Prensky, MD (investigator for Alimera Sciences) reported to the [Read More]
Headworn Video Devices Are Helping The Visually Impaired To See Better
by Dan Roberts (Updated 1/11/2019) Portable electronic magnifiers have come a long way in the past decade, improving clarity of vision for thousands. A natural development for those who prefer to have their hands free has been the creation of several types of headworn video devices, the leaders in the field being eSight, NuEyes, and [Read More]